DCM
TAK icon

Diag Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Diag Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$2.98M Buy
+177,260
New +$2.99M 3.41% 12

Other funds holding TAK

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
CCM
Causeway Capital Management Los Angeles, California $9.24B AUM 21.27% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Diag Capital Management's TAK Position: Q4 2018 in Review

Diag Capital Management opened a new position in Takeda Pharmaceutical (TAK) in Q4 2018: 177,260 shares worth $2.98M. The stake represents 3.41% of the portfolio and ranks #12 among its holdings.

93 funds tracked by Wall St. Rank hold TAK as of Q4 2018.

  • Diag Capital Management held 177,260 shares of Takeda Pharmaceutical worth $2.98M as of Q4 2018.
  • Takeda Pharmaceutical was a new Diag Capital Management position in Q4 2018.
  • Takeda Pharmaceutical made up 3.41% of Diag Capital Management's portfolio in Q4 2018, its #12 holding.
  • 93 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.